Literature DB >> 31376910

Urgent Revascularization Strategies in Patients With Diabetes Mellitus and Acute Coronary Syndrome.

Lucas C Godoy1, Patrick R Lawler2, Michael E Farkouh2, Bronwyn Hersen3, José C Nicolau4, Vivek Rao5.   

Abstract

The prevalence of diabetes mellitus (DM) is rising globally and in Canada. Besides being a risk factor for the development of coronary artery disease, DM is also a marker of poor prognosis in patients with acute coronary syndrome (ACS), increasing the risks for ischemic and bleeding complications. Patients with DM have a high prevalence of multivessel coronary artery disease (MVD) and robust evidence has supported coronary artery bypass surgery (CABG) as the optimal revascularization strategy in the setting of stable ischemic heart disease. In the acute scenario, particularly in patients with non-ST-segment elevation (NSTE) ACS (NSTE-ACS), there are many uncertainties regarding the best revascularization strategy. Most guidelines suggest an invasive and timely approach (that is, performing coronary catheterization within 72 hours after the onset of the NSTE-ACS) and make recommendations about choosing between percutaneous coronary intervention (PCI) or CABG on the basis of data for patients with stable ischemic heart disease. Recent observational and subgroup analyses suggest that CABG might be the preferential method of revascularization for patients with DM and MVD also in the NSTE-ACS setting; however, dedicated randomized clinical trials are lacking. Finally, in patients who present with an ST-segment elevation myocardial infarction, the initial revascularization method of choice is generally PCI, instead of fibrinolysis or CABG, and DM status most often does not influence this decision. The management of residual MVD after primary PCI for ST-segment elevation myocardial infarction, however, remains controversial.
Copyright © 2019 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31376910     DOI: 10.1016/j.cjca.2019.03.010

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  6 in total

1.  The Protective Role of Bmal1-Regulated Autophagy Mediated by HDAC3/SIRT1 Pathway in Myocardial Ischemia/Reperfusion Injury of Diabetic Rats.

Authors:  Zhen Qiu; Hao Ming; Yi Zhang; Yanli Yu; Shaoqing Lei; Zhong-Yuan Xia
Journal:  Cardiovasc Drugs Ther       Date:  2021-02-23       Impact factor: 3.727

2.  Anxiety and clinical outcomes of patients with acute coronary syndrome: a meta-analysis.

Authors:  Jie Li; Feng Ji; Junxian Song; Xiangyang Gao; Deguo Jiang; Guangdong Chen; Suling Chen; Xiaodong Lin; Chuanjun Zhuo
Journal:  BMJ Open       Date:  2020-07-09       Impact factor: 2.692

3.  Impact of Hyperinsulinemia on Long-Term Clinical Outcomes of Percutaneous Coronary Intervention in Patients without Diabetes Who Have Acute Myocardial Syndrome.

Authors:  Qiang Tan; Ming Chen; Jia Hao; Kun Wei
Journal:  Diabetes Metab Syndr Obes       Date:  2021-09-07       Impact factor: 3.168

4.  Association of baseline hemoglobin A1c levels with bleeding in patients with non-ST-segment elevation acute coronary syndrome underwent percutaneous coronary intervention: insights of a multicenter cohort study from China.

Authors:  Hua-Lin Fan; Li-Huan Zeng; Peng-Yuan Chen; Yuan-Hui Liu; Chong-Yang Duan; Wen-Fei He; Ning Tan; Ji-Yan Chen; Peng-Cheng He
Journal:  J Geriatr Cardiol       Date:  2022-07-28       Impact factor: 3.189

5.  A novel 6-metabolite signature for prediction of clinical outcomes in type 2 diabetic patients undergoing percutaneous coronary intervention.

Authors:  Xue-Bin Wang; Ning-Hua Cui; Xia'nan Liu
Journal:  Cardiovasc Diabetol       Date:  2022-07-04       Impact factor: 8.949

6.  Downregulation of DEC1 by RNA interference attenuates ischemia/reperfusion-induced myocardial inflammation by inhibiting the TLR4/NF-κB signaling pathway.

Authors:  Weipan Xu; Kai Zhang; Yi Zhang; Shanxue Ma; Daoqun Jin
Journal:  Exp Ther Med       Date:  2020-04-30       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.